About us
  Research & Development
  Important Links
  Right to Information
Infectious Diseases & Immunology Division

Dr. Nahid Ali

Raja Ramanna Fellow
J C Bose National Fellow

PhD, Calcutta University, 1985
Contact - nali@iicb.res.in

Article Paper Sites:






http://www.irishsun.com/index.php/sid/239114553 https://in.news.yahoo.com/india-developed-blood-test-kala-azar-tested-africa-092005638.html











Current Research Interest

  • Diagnostic tools for kala-azar and PKDL.
  • Mechanism of immune regulation and drug induced immunomodulation in Indian kala-azar and PKDL.
  • Evaluation of vaccination strategies and protein- and DNA-based candidate  antigens.
  • Studies on immune stimulation pathways by liposomal vaccines.
  • Cationic liposome based combination therapy with existing drugs and novel compounds.
  • Study of host cell signaling during visceral leishmaniasis.
  • Validation of novel drug targets for the treatment of visceral leishmaniasis.
  • Development of strategies for cancer targeting by liposomal formulations.

Names of the group members including regular staff with designation and research fellows:


Ms. Amrita Das Banerjee, SRF (CSIR)

E Mail : amritaa.4u@gmail.com

Ms. Manjarika De, SRF (ICMR)

E Mail : de.manjarika@gmail.com

Ms. Roma Sinha, SRF (CSIR)

E Mail : sinha.roma27@gmail.com

Mr. Pradyot Bhattacharya, SRF (ICMR)

E Mail : b_pradyot@yahoo.com

Md. Asad, SRF (ICMR)

E Mail : asadseraphic.nii@gmail.com

Md. Shadab, SRF (CSIR)

E Mail : shadab.bio@gmail.com

Mr. Sarfaraz Ahmad Ejazi, SRF (CSIR)

E Mail : sarfaraz.ejazi@hotmail.com

Ms. Rudra Chhajer, SRF (CSIR)

E Mail : justrudra@gmail.com

Mr. Somsubra Thakur Choudhury, SRF (CSIR)

E Mail : sthakurchoudhury@gmail.com

Mr. Abdus Sabur, SRF (UGC)

E Mail : absab2007@gmail.com

Ms. Nicky Didwania, JRF (UGC)

E Mail : didwanianicky@gmail.com

Mr. Anirban Bhattacharyya, PF (CSIR)

E Mail : anirbanbiomedical@gmail.com

List of important Publications:

  1. Sinha R, Roychoudhury J, Palit P, Ali N. Cationic liposomal-sodium  stibogluconate (SSG): A potent therapeutic tool for the treatment of SSG-sensitive and -resistant Leishmania donovani infection. Antimicrobial Agents and Chemotherapy, 2014, pii: AAC.03305-14. [Epub ahead of print].
  2. Das A. and Ali N. Combining cationic liposomal delivery with TLR4 ligand for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection. PLOS Neglected Tropical Diseases. 2014, 8(8), 1-17.
  3. Chhajer R and Ali N. Genetically modified organisms and visceral leishmaniasis. Frontiers in Immunology, 2014, 5, 1-10.
  4. Md Asad and Ali N. Dynamicity of immune regulation during visceral leishmaniasis. Proc Indian National Science Academy, 80 No. 2 June 2014 pp.
  5. Bhowmick S, Ravindran R, Ali N. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine. BMC Microbiology. 2014, 14, 1-12.
  6. Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 2013, 46(2), 128-134.
  7. Ejazi SA, Ali N. Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Review of Anti-Infective Therapy, 2013, 11(1), 79-98.
  8. Das A and Ali N. Vaccine development against Leishmania donovani. Frontiers in Microbial Immunology, 2012, 3,1-19.
  9. Palit P, Hazra A, Maity A, Vijayan RS, Manoharan P, Banerjee S, Mondal NB, Ghoshal N, Ali N. Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012, 56, 432-445.
  10. Ravindran R, Maji M, Ali NVaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Molecular Pharmaceutics, 2012, 9, 59-70.
  11. Mazumder S, Maji M and Ali N. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection. PLoS Neglected Tropical Diseases, 2011, 5, 1-13.
  12. Palit P, Hazra A, Maity A, Vijayan RS, Manoharan P, Banerjee S, Mondal NB, Ghoshal N, Ali N. Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 2012, 56, 432-445.
  13. The Working Group on Research Priorities for Development of Leishmaniasis Vaccines, Costa CH, Peters NC, Ali N, Maruyama SR, de Brito EC Jr, Santos IK. Vaccines for the leishmaniases: proposals for a research agenda.  PLos Neglected Tropical Diseases, 2011, 5(3), 1-9.
  14. Saha S,  Goswami R, Pramanik N, Guha SK, Saha B, Rahman M, Mallick S, Modak  D, Silva FO, Mendonca IL, Costa DL, Costa CHN, and Ali N. Development and evaluation of Leishmania donovani Promastigote membrane antigen-based serodiagnosis of visceral leishmaniasis and post Kala-azar dermal leishmaniasis. Emerging Infectious Diseases, 2011, 17, 1304-1306.
  15. Mazumder, S, Maji M, Das, A and Ali N. Potency, efficacy and durability of DNA/DNA, DNA /protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c Mice. PLoS ONE, 2011, 6, 1-15.
  16. Banerjee, A., De, M., and Ali N. Combination therapy with paromomycin associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrobial Agents and Chemotherapy, 2011, 55, 1661-1670.
  17. Mondal S, Bhattacharya P and Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Review on Anti-Infective Therapy, 2010, 8, 919-944.
  18. Mondal S, Bhattacharya P, Rahaman M, Ali N and Goswami R. P. A curative immune profile one-week after treatment of Indian kala-azar patients predicts success with short-course liposomal amphotericin B therapy. PLos Neglected Tropical Diseases, 2010, 4, 1-8.
  19. Sinha R, Sengupta A, Ali N and Gupta P. N. Is PGL-I really a specific antigen for leprosy? Clinical Infectious Diseases, 2010, 50, 937-938.
  20. Bhowmick S, Mazumdar T, Sinha R and Ali N. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. Journal of Controlled Release, 2010, 141, 199-207.
  21. Bhowmick S., and Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PLoS ONE. 2009, 4, 1-10.
  22. Banerjee A., De M., and Ali NComplete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. Journal of Immunology, 2008, 181, 1386-1398.
  23. Bhowmick S., and Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert Opinion on Drug Delivery. 2008, 7, 789-803.
  24. Banerjee A., Roychoudhury J., and Ali N. Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. Journal of Antimicrobial Chemotherapy, 2008, 61, 103-110.
  25. Palit P., and Ali N. Oral Therapy with Amlodipine and Lacidipine, 1, 4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis. Antimicrobial Agents Chemotherapy. 2008, 52, 374-377.
  26. Saha, S., Mondal, S., Ravindran, R., Bhowmik, S., Modak, D., Mallick, S., Rahman, M., Kar, S., Goswami, R., Guha, SK., Pramanik, N., Saha, B., Ali N. IL-10 and TGF-β mediated susceptibility in Post-kala-azar-dermal leishmaniasis: The significance of amphotericin B in the control of Leishmania donovani infection in India. Journal of Immunology, 2007, 179, 5592-5603.

Detail list of Publications upto November'2014 ==>> Click here


Back to Main
Updated on 28th November'2014
Animal House Publication & Information